Skip to main content

Advertisement

SpringerLink
Log in

Insulin resistance and heart failure

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Despite recent therapeutic advances, heart failure remains a leading cause of morbidity and mortality. The prevalence of heart failure continues to rise, and the importance of cardiac energetics underlying myocardial dysfunction is increasingly recognized. The rise in obesity and type 2 diabetes with associated insulin resistance results in abnormal glucose and fatty acid metabolism of the myocardium and the entire body, serving to highlight the fact that deranged metabolism may provide a therapeutic target beyond existing neuroendocrine inhibition. Evidence from clinical studies often conflict, but it appears that the association between heart failure and insulin resistance is interdependent and complex. Drugs that improve glucose metabolism may harm myocardial performance under stress, and the use of metabolic treatment in patients with heart failure must be targeted on the individual and based on evidence from carefully designed clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ioannou GN, Bryson CL, Boyko EJ: Prevalence and trends of insulin resistance, impaired fasting glucose, and diabetes. J Diabetes Complications 2007, 21:363–370.

    Article  PubMed  Google Scholar 

  2. Lloyd-Jones DM, Larson MG, Leip EP, et al.: Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002, 106:3068–3072.

    Article  PubMed  Google Scholar 

  3. Leyden D: Asthma und diabetes mellitus. Zeitschr Klin Med 1881, 3:358–364.

    Google Scholar 

  4. Goulston A: A note on the beneficial effect of the ingestion of cane sugar in certain forms of heart disease. Br J Med 1911, i:615.

    Article  Google Scholar 

  5. Cohen-Solal A, Beauvais F, Logeart D: Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail 2008, 14:615–625.

    Article  PubMed  Google Scholar 

  6. Swan JW, Anker SD, Walton C, et al.: Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997, 30:527–532.

    Article  PubMed  CAS  Google Scholar 

  7. Nikolaidis LA, Sturzu A, Stolarski C, et al.: The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 2004, 61:297–306.

    Article  PubMed  CAS  Google Scholar 

  8. MacDonald MR, Petrie MC, Hawkins NM, et al.: Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008, 29:1224–1240.

    Article  PubMed  CAS  Google Scholar 

  9. Kannel WB, Hjortland M, Castelli WP: Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974, 34:29–34.

    Article  PubMed  CAS  Google Scholar 

  10. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405–412.

    Article  PubMed  CAS  Google Scholar 

  11. Ingelsson E, Sundstrom J, Arnlov J, et al.: Insulin resistance and risk of congestive heart failure. JAMA 2005, 294:334–341.

    Article  PubMed  CAS  Google Scholar 

  12. Ferrannini E, Galvan AQ, Gastaldelli A, et al.: Insulin: new roles for an ancient hormone. Eur J Clin Invest 1999, 29:842–852.

    Article  PubMed  CAS  Google Scholar 

  13. Gibbs CL: Cardiac energetics. Physiol Rev 1978, 58:174–254.

    PubMed  CAS  Google Scholar 

  14. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85:1093–1129.

    Article  PubMed  CAS  Google Scholar 

  15. Opie LH: The Heart: Physiology and Metabolism, edn 2. New York: Raven Press; 1991.

    Google Scholar 

  16. Opie LH: The metabolic vicious cycle in heart failure. Lancet 2004, 364:1733–1734.

    Article  PubMed  Google Scholar 

  17. Pessin JE, Thurmond DC, Elmendorf JS, et al.: Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. Location! Location! Location! J Biol Chem 1999, 274:2593–2596.

    Article  PubMed  CAS  Google Scholar 

  18. Rider MH, Hue L: Activation of rat heart phosphofructokinase-2 by insulin in vivo. FEBS Lett 1984, 176:484–488.

    Article  PubMed  CAS  Google Scholar 

  19. Gamble J, Lopaschuk GD: Insulin inhibition of 5′ adenosine monophosphate-activated protein kinase in the heart results in activation of acetyl coenzyme A carboxylase and inhibition of fatty acid oxidation. Metabolism 1997, 46:1270–1274.

    Article  PubMed  CAS  Google Scholar 

  20. Beutler B, Cerami A: Cachectin: more than a tumor necrosis factor. N Engl J Med 1987, 316:379–385.

    PubMed  CAS  Google Scholar 

  21. How OJ, Aasum E, Severson DL, et al.: Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006, 55:466–473.

    Article  PubMed  CAS  Google Scholar 

  22. Iozzo P, Chareonthaitawee P, Dutka D, et al.: Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002, 51:3020–3024.

    Article  PubMed  CAS  Google Scholar 

  23. Doehner W, von Haehling S, Anker SD: Insulin resistance in chronic heart failure. J Am Coll Cardiol 2008, 52:239.

    Article  PubMed  Google Scholar 

  24. Tuunanen H, Engblom E, Naum A, et al.: Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006, 114:2130–2137.

    Article  PubMed  CAS  Google Scholar 

  25. Raher MJ, Thibault HB, Buys ES, et al.: A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload. Am J Physiol Heart Circ Physiol 2008, 295:H2459–H2502.

    Article  CAS  Google Scholar 

  26. Amato L, Paolisso G, Cacciatore F, et al.: Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 1997, 23:213–218.

    PubMed  CAS  Google Scholar 

  27. Tenenbaum A, Motro M, Fisman EZ, et al.: Functional class in patients with heart failure is associated with the development of diabetes. Am J Med 2003, 114:271–275.

    Article  PubMed  Google Scholar 

  28. Coats AJ, Anker SD: Insulin resistance in chronic heart failure. J Cardiovasc Pharmacol 2000, 35(7 Suppl 4):S9–S14. [Published erratum appears in J Cardiovasc Pharmacol 2001, 38:490.]

    Article  PubMed  CAS  Google Scholar 

  29. Opie LH, Thandroyen FT, Muller C, Bricknell OL: Adrenaline-induced “oxygen-wastage” and enzyme release from working rat heart. Effects of calcium antagonism, beta-blockade, nicotinic acid and coronary artery ligation. J Mol Cell Cardiol 1979, 11:1073–1094.

    Article  PubMed  CAS  Google Scholar 

  30. Paolisso G, De Riu S, Marrazzo G, et al.: Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 1991, 40:972–977.

    Article  PubMed  CAS  Google Scholar 

  31. Paolisso G, Manzella D, Rizzo MR, et al.: Elevated plasma fatty acid concentrations stimulate the cardiac autonomic nervous system in healthy subjects. Am J Clin Nutr 2000, 72:723–730.

    PubMed  CAS  Google Scholar 

  32. Roden M: How free fatty acids inhibit glucose utilization in human skeletal muscle. News Physiol Sci 2004, 19:92–96.

    PubMed  CAS  Google Scholar 

  33. Marangou AG, Alford FP, Ward G, et al.: Hormonal effects of norepinephrine on acute glucose disposal in humans: a minimal model analysis. Metabolism 1988, 37:885–891.

    Article  PubMed  CAS  Google Scholar 

  34. Nonogaki K: New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000, 43:533–549.

    Article  PubMed  CAS  Google Scholar 

  35. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.

    Article  PubMed  CAS  Google Scholar 

  36. Leichman JG, Wilson EB, Scarborough T, et al.: Dramatic reversal of derangements in muscle metabolism and left ventricular function after bariatric surgery. Am J Med 2008, 121:966–973.

    Article  PubMed  CAS  Google Scholar 

  37. Andraws R, Brown DL: Effect of inhibition of the reninangiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007, 99:1006–1012.

    Article  PubMed  CAS  Google Scholar 

  38. Al-Hesayen A, Azevedo ER, Floras JS, et al.: Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. Eur J Heart Fail 2005, 7:618–623.

    Article  PubMed  CAS  Google Scholar 

  39. Kovacic D, Marinsek M, Gobec L, et al.: Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol 2008, 97:24–31.

    Article  PubMed  CAS  Google Scholar 

  40. Alan S, Ulgen MS, Dedeoglu I, et al.: Long-term glucose insulin potassium infusion improves systolic and diastolic function in patients with chronic ischemic cardiomyopathy. Swiss Med Wkly 2003, 133:419–422.

    PubMed  CAS  Google Scholar 

  41. Eurich DT, Majumdar SR, McAlister FA, et al.: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28:2345–2351.

    Article  PubMed  CAS  Google Scholar 

  42. Eurich DT, McAlister FA, Blackburn DF, et al.: Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007, 335:497.

    Article  PubMed  CAS  Google Scholar 

  43. Nissen SE, Nicholls SJ, Wolski K, et al.: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008, 299:1561–1573.

    Article  PubMed  CAS  Google Scholar 

  44. Guan Y, Hao C, Cha DR, et al.: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005, 11:861–866.

    Article  PubMed  CAS  Google Scholar 

  45. Zanchi A, Chiolero A, Maillard M, et al.: Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004, 89:1140–1145.

    Article  PubMed  CAS  Google Scholar 

  46. Sokos GG, Nikolaidis LA, Mankad S, et al.: Glucagonlike peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694–699.

    Article  PubMed  CAS  Google Scholar 

  47. Nystrom T: The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 2008, 40:593–606.

    Article  PubMed  CAS  Google Scholar 

  48. Fragasso G, Palloshi A, Puccetti P, et al.: A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006, 48:992–998.

    Article  PubMed  CAS  Google Scholar 

  49. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD: Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996, 93:135–142.

    PubMed  CAS  Google Scholar 

  50. Belardinelli L, Shryock JC, Fraser H: Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006, 92(Suppl 4):iv6–iv14.

    Article  PubMed  CAS  Google Scholar 

  51. Sossalla S, Wagner S, Rasenack EC, et al.: Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts—role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008, 45:32–43.

    Article  PubMed  CAS  Google Scholar 

  52. Rastogi S, Sharov VG, Mishra S, et al.: Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 2008, 295:H2149–H2155.

    Article  PubMed  CAS  Google Scholar 

  53. Lee L, Campbell R, Scheuermann-Freestone M, et al.: Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005, 112:3280–3288.

    Article  PubMed  CAS  Google Scholar 

  54. Schmidt-Schweda S, Holubarsch C: First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000, 99:27–35.

    Article  CAS  Google Scholar 

  55. Holubarsch CJ, Rohrbach M, Karrasch M, et al.: A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 2007, 113:205–212.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, University of Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ, UK

    David P. Dutka

Authors
  1. Patrick M. Heck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David P. Dutka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David P. Dutka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heck, P.M., Dutka, D.P. Insulin resistance and heart failure. Curr Heart Fail Rep 6, 89–94 (2009). https://doi.org/10.1007/s11897-009-0014-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-009-0014-8

Keywords

Search

Navigation